Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia

Qing Zhang, Shaochun Bai, Gail H. Vance

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) and a normal karyotype constitute the single largest cytogenetic group of AML. It is important to identify prognostic markers that predict patients' outcome more precisely. The presence of mutations in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize therapeutic approaches in this group of patients. Polymerase chain reaction (PCR)-based fragment length analysis for mutations in FLT3 and NPM1 has been shown to be a fast and sensitive method, while nucleotide sequencing represents a gold standard for CEBPA heterogeneous mutational screening. We describe both fragment length assay and sequencing methods for mutational analysis of these three genes.

Original languageEnglish (US)
Title of host publicationHematological Malignancies
Pages105-121
Number of pages17
DOIs
StatePublished - Sep 4 2013

Publication series

NameMethods in Molecular Biology
Volume999
ISSN (Print)1064-3745

Fingerprint

CCAAT-Enhancer-Binding Protein-alpha
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Molecular Biology
Cytogenetics
Mutation
Karyotype
Genes
Nucleotides
Polymerase Chain Reaction

Keywords

  • Acute myeloid leukemia (AML)
  • Capillary electrophoresis
  • CEBPA
  • DNA sequencing
  • FLT3
  • Mutational detection
  • NPM1
  • PCR

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Zhang, Q., Bai, S., & Vance, G. H. (2013). Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. In Hematological Malignancies (pp. 105-121). (Methods in Molecular Biology; Vol. 999). https://doi.org/10.1007/978-1-62703-357-2-7

Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. / Zhang, Qing; Bai, Shaochun; Vance, Gail H.

Hematological Malignancies. 2013. p. 105-121 (Methods in Molecular Biology; Vol. 999).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhang, Q, Bai, S & Vance, GH 2013, Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. in Hematological Malignancies. Methods in Molecular Biology, vol. 999, pp. 105-121. https://doi.org/10.1007/978-1-62703-357-2-7
Zhang Q, Bai S, Vance GH. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. In Hematological Malignancies. 2013. p. 105-121. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-357-2-7
Zhang, Qing ; Bai, Shaochun ; Vance, Gail H. / Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. Hematological Malignancies. 2013. pp. 105-121 (Methods in Molecular Biology).
@inbook{7341feedb93942bf97570ecc4682f40b,
title = "Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia",
abstract = "Patients with acute myeloid leukemia (AML) and a normal karyotype constitute the single largest cytogenetic group of AML. It is important to identify prognostic markers that predict patients' outcome more precisely. The presence of mutations in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize therapeutic approaches in this group of patients. Polymerase chain reaction (PCR)-based fragment length analysis for mutations in FLT3 and NPM1 has been shown to be a fast and sensitive method, while nucleotide sequencing represents a gold standard for CEBPA heterogeneous mutational screening. We describe both fragment length assay and sequencing methods for mutational analysis of these three genes.",
keywords = "Acute myeloid leukemia (AML), Capillary electrophoresis, CEBPA, DNA sequencing, FLT3, Mutational detection, NPM1, PCR",
author = "Qing Zhang and Shaochun Bai and Vance, {Gail H.}",
year = "2013",
month = "9",
day = "4",
doi = "10.1007/978-1-62703-357-2-7",
language = "English (US)",
isbn = "9781627033565",
series = "Methods in Molecular Biology",
pages = "105--121",
booktitle = "Hematological Malignancies",

}

TY - CHAP

T1 - Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia

AU - Zhang, Qing

AU - Bai, Shaochun

AU - Vance, Gail H.

PY - 2013/9/4

Y1 - 2013/9/4

N2 - Patients with acute myeloid leukemia (AML) and a normal karyotype constitute the single largest cytogenetic group of AML. It is important to identify prognostic markers that predict patients' outcome more precisely. The presence of mutations in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize therapeutic approaches in this group of patients. Polymerase chain reaction (PCR)-based fragment length analysis for mutations in FLT3 and NPM1 has been shown to be a fast and sensitive method, while nucleotide sequencing represents a gold standard for CEBPA heterogeneous mutational screening. We describe both fragment length assay and sequencing methods for mutational analysis of these three genes.

AB - Patients with acute myeloid leukemia (AML) and a normal karyotype constitute the single largest cytogenetic group of AML. It is important to identify prognostic markers that predict patients' outcome more precisely. The presence of mutations in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize therapeutic approaches in this group of patients. Polymerase chain reaction (PCR)-based fragment length analysis for mutations in FLT3 and NPM1 has been shown to be a fast and sensitive method, while nucleotide sequencing represents a gold standard for CEBPA heterogeneous mutational screening. We describe both fragment length assay and sequencing methods for mutational analysis of these three genes.

KW - Acute myeloid leukemia (AML)

KW - Capillary electrophoresis

KW - CEBPA

KW - DNA sequencing

KW - FLT3

KW - Mutational detection

KW - NPM1

KW - PCR

UR - http://www.scopus.com/inward/record.url?scp=84883222737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883222737&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-357-2-7

DO - 10.1007/978-1-62703-357-2-7

M3 - Chapter

C2 - 23666693

AN - SCOPUS:84883222737

SN - 9781627033565

T3 - Methods in Molecular Biology

SP - 105

EP - 121

BT - Hematological Malignancies

ER -